COPIKTRA (duvelisib)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

Copiktra is a kinase inhibitor indicated for the treatment of adult patients with:

  • Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.
Coverage criteria:

For diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):

  • Patient is 18 years of age or older, AND
  • Prescribed by or in consultation with an oncologist, AND
  • Patient has tried and failed at least two prior systemic therapies.
Reauthorization Criteria: 

For diagnosis of CLL or SLL:

  • Patient dies not show evidence of progressive disease while on Copiktra therapy.
Authorization is not covered for the following: 
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Policy Updates:
  • 09/03/2019 - coverage criteria review
  • 05/17/2022 - removed criteria management of drug-drug interactions; added reauthorization criteria; removed coverage criteria for relapsed or refractory follicular lymphoma (FL) indication due to withdrawal by the FDA.

Last review date: May 17, 2022

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone